Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00017784
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2001-06-11
Brief Title:
Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
Sponsor:
Hoffmann-La Roche
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment
Status:
UNKNOWN
Status Verified Date:
2001-06
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to make valganciclovir available before it is approved for marketing to HIV-infected patients who have cytomegalovirus CMV retinitis eye infection and cannot take drugs by injection This study also will look at the safety of using valganciclovir as starting andor ongoing therapy
CMV can cause serious AIDS-related infections in patients with HIV Drugs that are effective against CMV eye infections can be given only by injection this calls for a thin tube to be placed into a vein in the chest so that the patient is not put through getting too many needle sticks An experimental drug valganciclovir is similar to 1 of these approved drugs ganciclovir but is more convenient and easier to use since it can be taken by mouth Once in the body valganciclovir changes to ganciclovir Studies have shown that valganciclovir tablets can result in the same level of ganciclovir in the blood as ganciclovir injection
CMV can cause serious AIDS-related infections in patients with HIV Drugs that are effective against CMV eye infections can be given only by injection this calls for a thin tube to be placed into a vein in the chest so that the patient is not put through getting too many needle sticks An experimental drug valganciclovir is similar to 1 of these approved drugs ganciclovir but is more convenient and easier to use since it can be taken by mouth Once in the body valganciclovir changes to ganciclovir Studies have shown that valganciclovir tablets can result in the same level of ganciclovir in the blood as ganciclovir injection
Detailed Description:
CMV causes sight- or life-threatening opportunistic infections in people with AIDS Intravenous agents including ganciclovir foscarnet and cidofovir are presently approved as treatments for CMV retinitis within this population Ganciclovir and foscarnet induction and maintenance therapy require daily infusions and usually require the use of long-term indwelling central venous catheters Although the treatment interval of cidofovir is longer administration necessitates the use of pre-hydration and probenecid in order to avoid a risk of renal toxicity Oral ganciclovir is an alternative to the intravenous formulation for the maintenance treatment of CMV retinitis However because blood levels achieved after oral ganciclovir are low compared to intravenous oral ganciclovir cannot be used for induction therapy In an attempt to improve the bioavailability of ganciclovir valganciclovir was developed Valganciclovir is a ganciclovir prodrug which when administered orally is rapidly converted to the active compound ganciclovir during a first-pass process with the majority of hydrolysis occurring pre-systemically Studies have shown that valganciclovir tablets allow systemic exposure of ganciclovir comparable to that achieved with recommended doses of intravenous ganciclovir
Patients undergo an ophthalmologic exam by an ophthalmologist and safety and other laboratory tests to establish eligibility No specific visits are requested by the drug usage plan following enrollment however patients should be seen for safety andor clinical assessments and medication dispensation at periodic visits consistent with standard of care An ophthalmologic exam should be performed again at Week 3 no later than Week 4 at the end of the induction treatment phase consistent with standard of care in order to ensure adequate response to therapy Valganciclovir is provided on a monthly basis and only as long as the patient is assessed and information provided in a timely manner This supply will be terminated 1 month subsequent to when the drug is available by prescription unless otherwise decided
Patients undergo an ophthalmologic exam by an ophthalmologist and safety and other laboratory tests to establish eligibility No specific visits are requested by the drug usage plan following enrollment however patients should be seen for safety andor clinical assessments and medication dispensation at periodic visits consistent with standard of care An ophthalmologic exam should be performed again at Week 3 no later than Week 4 at the end of the induction treatment phase consistent with standard of care in order to ensure adequate response to therapy Valganciclovir is provided on a monthly basis and only as long as the patient is assessed and information provided in a timely manner This supply will be terminated 1 month subsequent to when the drug is available by prescription unless otherwise decided
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ML16356 | None | None | None |